TABLE 1.
Comparison of the mono‐infected (SARS‐CoV‐2 only) and co‐infected (SARS‐CoV‐2 and one or more respiratory viruses) patient groups by secondary outcome measurements (Figure S7–S10)
| Secondary outcome | No. of studies | No. of patients (Events/Total) | p‐value | Relative effect (95% CI) | I‐squared | |
|---|---|---|---|---|---|---|
| SARS‐CoV‐2 co‐infected patients | SARS‐CoV‐2 mono‐infected patients | |||||
| Symptom cough | 5 | 82/131 (62.6%) | 136/225 (60.4%) | 0.21 | OR 0.72 (0.42–1.12) | 8% |
| Symptom fever | 5 | 95/131 (73.3%) | 171/225 (76.0%) | 0.12 | OR 0.63 (0.35–1.12) | 28% |
| Symptom dyspnoea | 5 | 63/131 (48.1%) | 84/225 (37.3%) | 0.94 | OR 0.97 (0.38–2.47) | 41% |
| ICU‐admission‐rate | 7 | 20/78 (25.6%) | 228/901 (25.3%) | 0.75 | OR 0.89 (0.42–1.87) | 0% |
| Case‐fatality‐rate | 10 | 37/203 (18.2%) | 42/626 (6.7%) | 0.48 | OR 1.66 (0.40–6.78) | 67% |
| Gender distribution | Co‐infections among males | Co‐infections among females | ||||
| 12 | 136/1357 (10.0%) | 133/1182 (11.3%) | 0.12 | OR 0.79 (0.59–1.06) | 0% | |
Abbreviations: CI, confidence interval; ICU, intensive care unit; OR, Odds ratio; SARS‐CoV‐2, Severe acute respiratory syndrome‐related coronavirus.